

What I claim is:

1. A method of treating the disease of a type selected from peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies, comprising administering an effective amount of a pharmaceutical composition comprising a cGMP PDE5 inhibitor or a derivative or salt thereof.
2. A method of treating a disease according to claim 1 wherein said disease is selected from the group consisting of Raynaud's Phenomenon, CREST syndrome, erythromatosis, rheumatoid diseases and diabetic retinopathies.
3. A method of treating onychiomycosis comprising administering an effective amount of a pharmaceutical composition comprising a cGMP PDE5 inhibitor or a derivative or salt thereof.
4. A method of treating a patient suffering from diabetic foot ulcers which comprises treating said patient with an effective amount of a pharmaceutical composition comprising a cGMP PDE5 inhibitor or a derivative or salt thereof.
5. A method of preventing the formation of foot ulcers in a patient suffering from the disease diabetes, the method comprising administering to said patient an effective amount of a pharmaceutical composition comprising a cGMP PDE5 inhibitor or a derivative or salt thereof.

BEST AVAILABLE COPY

6. A method of manufacturing a diabetic foot ulcer therapeutic comprising providing an effective ingredient selected from the group consisting of a cGMP PDE5 inhibitor, a derivative thereof, and a salt thereof and combining said effective ingredient with a suitable carrier for administration to a patient.

7. A method according to claim 4 or 5, wherein the cGMP PDE 5 inhibitor is sildenafil.